Roche Developing Diagnostic Assay To Predict Xeloda Response
Executive Summary
Roche is developing a tumor-specific assay to target the metastatic breast cancer therapy Xeloda (capecitabine) to patients more likely to respond.
You may also be interested in...
Roche Proteomics Group Focusing On Ways To Diagnosis Alzheimer's Disease
Measuring protein differences for the diagnosis and treatment of Alzheimer's disease is among the projects currently being pursued by Roche's proteomics group.
Roche Proteomics Group Focusing On Ways To Diagnosis Alzheimer's Disease
Measuring protein differences for the diagnosis and treatment of Alzheimer's disease is among the projects currently being pursued by Roche's proteomics group.
Herceptin First-Line Use In Breast Cancer Grows With 90% HER2 Testing
First-line use of Genentech's Herceptin (trastuzumab) is increasing with the growing number of breast cancer patients who are being tested for overexpression of the HER2 protein.